Erasca (ERAS) slides 6.4% as traders digest dilution overhang and recent insider sale; no clear single-day catalyst

Erasca, Inc. (ERAS) is down 6.4% today. Here is some analysis on what might have caused this price movement.

Analysis: There does not appear to be a single, company-specific headline that cleanly explains today’s drop. The move looks consistent with a volatility-driven pullback in a clinical-stage biotech following earlier financing-related dilution, plus sensitivity to insider-selling disclosures and elevated short interest.

Details:

Erasca completed an upsized public stock offering in January 2026, increasing share count and leaving a lingering dilution overhang that can pressure the stock during risk-off sessions.

A recent Form 4 showed an executive exercising options and selling shares in early April 2026, which can weigh on sentiment even when sales are planned or partly tax-related.

The company’s March 2026 business update and financial results reiterated its cash runway and pipeline milestones, but also underscored that near-term valuation is highly dependent on upcoming clinical readouts—often a setup for sharp swings on light news.

Short-interest data show a relatively large short position, which can amplify day-to-day moves when liquidity thins or momentum reverses.

Sources:

Erasca (Investor Relations), U.S. SEC, StockTitan, ChartExchange

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$ERAS Insider Trading Activity

$ERAS insiders have traded $ERAS stock on the open market 3 times in the past 6 months. Of those trades, 0 have been purchases and 3 have been sales.

Here’s a breakdown of recent trading of $ERAS stock by insiders over the last 6 months:

EBUN GARNER (Chief Legal Officer) has made 0 purchases and 2 sales selling 200,000 shares for an estimated $1,982,812.
SHANNON MORRIS (Chief Medical Officer) sold 20,000 shares for an estimated $300,760

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

EARLY ACCESS

Receive ERAS Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$ERAS Hedge Fund Activity

We have seen 75 institutional investors add shares of $ERAS stock to their portfolio, and 68 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 15,445,081 shares (-76.3%) from their portfolio in Q4 2025, for an estimated $57,455,701
LOGOS GLOBAL MANAGEMENT LP removed 2,150,000 shares (-14.2%) from their portfolio in Q4 2025, for an estimated $7,998,000
STATE STREET CORP added 2,145,386 shares (+53.2%) to their portfolio in Q4 2025, for an estimated $7,980,835
EXODUSPOINT CAPITAL MANAGEMENT, LP added 1,490,967 shares (+inf%) to their portfolio in Q4 2025, for an estimated $5,546,397
SIO CAPITAL MANAGEMENT, LLC removed 1,369,748 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $5,095,462
ROCK SPRINGS CAPITAL MANAGEMENT LP added 951,710 shares (+inf%) to their portfolio in Q4 2025, for an estimated $3,540,361
IKARIAN CAPITAL, LLC added 735,396 shares (+inf%) to their portfolio in Q4 2025, for an estimated $2,735,673

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$ERAS Analyst Ratings

Wall Street analysts have issued reports on $ERAS in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Guggenheim issued a "Buy" rating on 11/14/2025
Stifel issued a "Buy" rating on 10/16/2025

To track analyst ratings and price targets for $ERAS, check out Quiver Quantitative's $ERAS forecast page.

$ERAS Price Targets

Multiple analysts have issued price targets for $ERAS recently. We have seen 9 analysts offer price targets for $ERAS in the last 6 months, with a median target of $19.0.

Here are some recent targets:

Anupam Rama from JP Morgan set a target price of $25.0 on 03/18/2026
Michael Schmidt from Guggenheim set a target price of $20.0 on 03/16/2026
Andres Y. Maldonado from HC Wainwright & Co. set a target price of $20.0 on 03/13/2026
Joseph Catanzaro from Mizuho set a target price of $19.0 on 03/13/2026
Kelsey Goodwin from Piper Sandler set a target price of $18.0 on 03/13/2026
Kaveri Pohlman from Clear Street set a target price of $20.0 on 03/06/2026
Laura Prendergast from Stifel set a target price of $4.0 on 10/16/2025

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.